NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









FoRx Therapeutics

FoRx Therapeutics

Private
BaselHealthcare & Life Scienceshttps://www.forxtherapeutics.com/

Last Round

Series A

Dec 18, 2025

Total Funding Raised

$60.85M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

FoRx Therapeutics is a biotechnology company that develops a new generation of first-in-class oral small molecule cancer drugs focusing on novel DNA Replication Stress pathways.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

small molecule therapeuticsoncologyDNA damage responseDDRDNA replication stressDRSPARG inhibitorprecision medicinedrug discoverysolid tumorsbiotechclinical stage biotechcancer therapydrug developmenttargeted therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FoRx Therapeutics Comps

Public and private peers based on sector, stage, and business model.

FoRx Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

FoRx Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 18, 2025
SeedApr 22, 2020

FoRx Therapeutics Investors

Notable investors and investment history

FoRx Therapeutics investors
InvestorRounds
Omega FundsSeed
EQT Life SciencesSeed, Series A
M VenturesSeries A, Seed
Pfizer VenturesSeed, Series A
PfizerSeed, Series A
Pfizer VenturesSeed, Series A
M VenturesSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 26, 2026

    FORX-428 shows potential for best-in-class PARG inhibition.

  • Mar 26, 2026

    Presented preclinical data for FORX-428 at ACS Spring 2026.

FoRx Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

FoRx Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about FoRx Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBasel
Employee Range34
Year Founded2019
Last FundingDec 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.